Impax Laboratories, Inc. (NASDAQ:IPXL) has been assigned a $17.00 target price by stock analysts at Royal Bank Of Canada in a report issued on Thursday. The brokerage currently has a “hold” rating on the specialty pharmaceutical company’s stock. Royal Bank Of Canada’s price objective would indicate a potential downside of 6.59% from the company’s previous close.

IPXL has been the subject of a number of other reports. Canaccord Genuity set a $19.00 price target on Impax Laboratories and gave the company a “hold” rating in a research report on Wednesday. Vetr lowered Impax Laboratories from a “strong-buy” rating to a “strong sell” rating and set a $10.55 price target for the company. in a research report on Monday, May 1st. Cantor Fitzgerald set a $20.00 price target on Impax Laboratories and gave the company a “buy” rating in a research report on Wednesday. Deutsche Bank AG set a $21.00 price target on Impax Laboratories and gave the company a “buy” rating in a research report on Monday, July 17th. Finally, Zacks Investment Research lowered Impax Laboratories from a “hold” rating to a “strong sell” rating in a research report on Monday, July 24th. Four investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $18.56.

Shares of Impax Laboratories (NASDAQ:IPXL) opened at 18.20 on Thursday. Impax Laboratories has a 1-year low of $7.75 and a 1-year high of $27.29. The stock has a 50 day moving average price of $17.28 and a 200 day moving average price of $14.30. The company’s market capitalization is $1.30 billion.

Impax Laboratories (NASDAQ:IPXL) last posted its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported $0.18 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.14 by $0.04. Impax Laboratories had a positive return on equity of 9.05% and a negative net margin of 71.08%. The company had revenue of $202.08 million during the quarter, compared to analyst estimates of $195.62 million. During the same period in the previous year, the business earned $0.21 EPS. Impax Laboratories’s quarterly revenue was up 17.1% on a year-over-year basis. On average, equities analysts anticipate that Impax Laboratories will post $0.68 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Royal Bank Of Canada Analysts Give Impax Laboratories, Inc. (IPXL) a $17.00 Price Target” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://www.watchlistnews.com/impax-laboratories-inc-ipxl-rating-reiterated-by-royal-bank-of-canada/1468908.html.

Hedge funds have recently made changes to their positions in the stock. Norges Bank bought a new stake in shares of Impax Laboratories during the fourth quarter valued at about $16,669,000. Quadrature Capital Ltd bought a new stake in shares of Impax Laboratories during the fourth quarter valued at about $224,000. GW&K Investment Management LLC boosted its stake in shares of Impax Laboratories by 3.1% in the first quarter. GW&K Investment Management LLC now owns 777,095 shares of the specialty pharmaceutical company’s stock valued at $9,830,000 after buying an additional 23,142 shares during the last quarter. Bank of Montreal Can boosted its stake in shares of Impax Laboratories by 60.4% in the first quarter. Bank of Montreal Can now owns 53,874 shares of the specialty pharmaceutical company’s stock valued at $681,000 after buying an additional 20,288 shares during the last quarter. Finally, Louisiana State Employees Retirement System boosted its stake in shares of Impax Laboratories by 1.0% in the first quarter. Louisiana State Employees Retirement System now owns 30,000 shares of the specialty pharmaceutical company’s stock valued at $380,000 after buying an additional 300 shares during the last quarter. Institutional investors and hedge funds own 83.48% of the company’s stock.

About Impax Laboratories

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Analyst Recommendations for Impax Laboratories (NASDAQ:IPXL)

Receive News & Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.